Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Yamaguchi S, Hirata K, Toyonaga T, Kobayashi K, Ishi Y, Motegi H, Kobayashi H, Shiga T, Tamaki N, Terasaka S, Houkin K. Yamaguchi S, et al. Among authors: shiga t. PLoS One. 2016 Dec 9;11(12):e0167917. doi: 10.1371/journal.pone.0167917. eCollection 2016. PLoS One. 2016. PMID: 27936194 Free PMC article.
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Narita T, Aoyama H, Hirata K, Onodera S, Shiga T, Kobayashi H, Murata J, Terasaka S, Tanaka S, Houkin K. Narita T, et al. Among authors: shiga t. Jpn J Clin Oncol. 2012 Feb;42(2):120-3. doi: 10.1093/jjco/hyr181. Epub 2011 Dec 23. Jpn J Clin Oncol. 2012. PMID: 22198964
¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, Yamaguchi S, Houkin K, Tanaka S, Kuge Y, Tamaki N. Hirata K, et al. Among authors: shiga t. Eur J Nucl Med Mol Imaging. 2012 May;39(5):760-70. doi: 10.1007/s00259-011-2037-0. Epub 2012 Feb 4. Eur J Nucl Med Mol Imaging. 2012. PMID: 22307533 Free article. Clinical Trial.
Usefulness of FMISO-PET for glioma analysis.
Kobayashi H, Hirata K, Yamaguchi S, Terasaka S, Shiga T, Houkin K. Kobayashi H, et al. Among authors: shiga t. Neurol Med Chir (Tokyo). 2013;53(11):773-8. doi: 10.2176/nmc.ra2013-0256. Epub 2013 Oct 29. Neurol Med Chir (Tokyo). 2013. PMID: 24172591 Free PMC article. Review.
Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.
Yamaguchi S, Hirata K, Kaneko S, Kobayashi H, Shiga T, Kobayashi K, Onimaru R, Shirato H, Tamaki N, Terasaka S, Houkin K. Yamaguchi S, et al. Among authors: shiga t. Acta Neurochir (Wien). 2015 Feb;157(2):187-94. doi: 10.1007/s00701-014-2290-7. Epub 2014 Dec 10. Acta Neurochir (Wien). 2015. PMID: 25488176
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, Terasaka S, Kobayashi H, Hattori N, Shiga T, Kuge Y, Tanaka S, Ito YM, Tamaki N. Toyonaga T, et al. Among authors: shiga t. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):611-619. doi: 10.1007/s00259-016-3541-z. Epub 2016 Oct 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 27752745 Free article.
1,153 results